

Emerging Female Contraception

Product	Phase	Description	Researchers	Organization	Availability
Non-Hormonal Ring (Ovaprene)	Preclinical testing	The contraceptive ring releases ferrous gluconate, ascorbic acid, and glycine. It keeps vaginal pH at a relatively stable level, at an average of 4.5. The ferrous gluconate binds to sperm and, on microscopy, has been shown to block sperm motility almost completely.	Giuseppe del Priore, Young Han, Mukul Singh, Brij Saxena	New York-Presbyterian Healthcare; Poly-Med, Inc	
Implanon	Phase 4	Implanon's active ingredient is Etonogestrel Organon, which is a synthetic form of the naturally occurring female sex hormone, progesterone. The etonogestrel implant is injected under the skin of the arm to slowly release the hormone into the body, maintaining a high level of the hormone in the blood. It provides contraception for 3 years but can be removed at any time by your doctor or family planning nurse. Etonogestrel works by tricking the body into thinking that ovulation has already occurred, by maintaining high levels of the synthetic progesterone which prevents the release of eggs from the ovaries. It also increases the thickness of this mucus by affecting the natural mucus at the neck of the womb (cervix) making it more difficult for sperm to cross from the vagina into the womb.	Philip Darney, Ashlesha Patel, Kimberly Rosen, Lena S. Shapiro, Andrew M. Kaunitz	San Francisco General Hospital; NV Organon, part of Schering-Plough Corporation	
Nestorone transdermal spray-Metered Dose Transdermal System (MDTS)	Preclinical testing	Weak study. Nestorone is a metered spray delivery contraceptive with progestogen. Nestorone possibly blocks ovulation. Only low doses are required for contraceptive efficacy.	Ian Fraser, Edith Weisberg, Narender Kumar, Sushama Kumer, Andrew Humberstone, Louise McCrossin, Deborah Shaw, YY Tsong, Regine Sitruk-Ware	University of Sydney, Sydney Centre for Reproductive Health Research, Center for Biomedical Research, Center for Pharmaceutical Research ; Population Council and Acrux Ltd	
Ethinyl estradiol/Nestorone ring	Phase 3	Vaginal ring containing EE and nestorone, a new anti-androgenic progestin		Population Council	If results of studies are favorable, expect FDA application by 2010
Ethinyl estradiol/Nestorone gel-Advanced Transdermal Delivery (ATD)	Phase 2	Sustained release advanced transdermal gel which is delivered systemically.		Population Council; Antares Pharma	
Savvy/ C31G (for contraception)	Phase 3	C31G is a broad-spectrum antibacterial agent that shows contraceptive properties in vitro. C31G is administered intravaginally via a prefilled applicator prior to sexual intercourse.		Biosyn; Cellegy	
Ushercell/ cellulose sulfate (for contraception)	Phase 2	Topically applied vaginal gel.		Polydex Pharmaceuticals; CONRAD; Rush Univ.	
Elcometrine	Phase 1	Nestorone transdermal		Population Council; Aveva Drug Delivery systems	
Elcometrine-based contraceptive	Phase 1	Nestorone transdermal		Population Council; Antares Pharma	
Ethinylestradiol/ levonoregesterol transdermal (AG 200/15)	Phase 2	Once-weekly, low-dose transdermal contraceptive patch.		Agile Therapeutics	
Ethinylestradiol/ norgestrel monophasic	Phase 3	Progestomimetic monophasic oral contraceptive.		Theramex/Organon	
Lunelle (subcutaneous)	Phase 2	Subcutaneous implantable version of injectible Lunelle		Pfizer	
Nonoxinol-9 liposomal	Phase 1	Spermicide		Novavax	
ORG 201745	Phase 1			Organon	
Trimegestone (as contraception)	Preclinical testing	Norpregnane progestin		Sanofi-Aventis, ProStrakan, Barr Laboratories	
Triple hormone contraception	Preclinical testing	Combination of estrogens and progestins with androgens, such as testosterone.		BioSante, Pantarhei	